When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. Meloxicam/rizatriptan - Wikipedia

   en.wikipedia.org/wiki/Meloxicam/rizatriptan

   Meloxicam/rizatriptan, sold under the brand name Symbravo, is a fixed-dose combination medication used for the treatment of migraine. [1] It is a combination of meloxicam, a nonsteroidal anti-inflammatory medication; and rizatriptan (as rizatriptan benzoate), a serotonin (5-HT) 1B/1D receptor agonist . [1] It is taken by mouth. [1]

3. FDA approves new pain medication as an alternative to ... - AOL

   www.aol.com/news/fda-approves-pain-medication...

   For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

4. Atogepant - Wikipedia

   en.wikipedia.org/wiki/Atogepant

   The UK’s National Institute for Health and Care Excellence has issued draft guidance recommending atogepant for preventing episodic and chronic migraine in NHS patients. It's approved for those experiencing at least 4 migraine days per month after failing 3 prior treatments. Atogepant costs £463 monthly but includes a confidential discount. [12]

5. FDA approves Pfizer's new nasal spray treatment for migraines

   www.aol.com/entertainment/fda-approves-pfizers...

   The U.S. Food and Drug Administration has approved Pfizer's newest drug on the migraine market, Zavzpret (zavegepant) -- the first and only migraine treatment of its kind to be offered in nasal spray.

6. FDA approves new type of non-opioid pain medication, 1st of ...

   www.aol.com/news/fda-approves-type-non-opioid...

   The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx ...

7. Erenumab - Wikipedia

   en.wikipedia.org/wiki/Erenumab

   The results were measured as mean monthly migraine days in months 4, 5, and 6. At baseline the patients experienced between 4 and 14 migraine days per month with an average of 8.3. The medication significantly reduced the number of migraine days per month by 3.2 in the 70-mg group and 3.7 in the 140-mg group, versus 1.8 in the placebo (0-mg) group.